Identifying specific factors that increase the likelihood of a complete remission provides valuable information to guide treatment decisions and improve long-term outcomes for patients with pancreatic cancer.
Preoperative radiotherapy, and especially preoperative stereotactic body radiotherapy, was found to be associated with a higher rate of complete remission of pancreatic cancer. Photo: Shutterstock.
A recent multicenter cohort study has revealed promising findings on the relationship between remission Complete pathology and survival in patients with localized pancreatic adenocarcinoma.
According to the research, those patients who achieved a remission complete after receiving chemoradiotherapy preoperative and resection showed a significantly higher five-year overall survival rate. This study, led by Dr. Thomas F. Stoop from the University of Amsterdam, takes an in-depth look at the factors influencing these outcomes, providing a solid foundation for improving treatment strategies in the pancreatic cancer.
The chemoradiotherapy Preoperative surgery is increasingly implemented in patients with localized pancreatic adenocarcinoma. This treatment modality has the potential to significantly increase the chances of a successful outcome. remission complete pathological, defined as the absence of viable tumor cells in the resected tissue sample.
Previously, evidence on the remission The complete review was based on data from large national databases or small single-center series, lacking multicenter studies with detailed and exhaustive data.
In this analysis, researchers studied the incidence and factors associated with remission Complete pathological examination in a total of 1,758 patients with localized pancreatic adenocarcinoma.
A must be achieved remission complete to improve survival rates
These patients, with a mean age of 64 years and 50% men, were treated at 19 centers located in eight different countries. All participants underwent resection after receiving at least two cycles of chemotherapy, with or without chemotherapy. radiotherapyThe median follow-up was 19 months, providing a sufficient time frame to assess long-term outcomes.
The results of the study showed that the rate of remission Complete pathological analysis was 4.8% in patients who received chemoradiotherapy before resection. This remission was associated with a 54% lower risk of death compared to those who did not achieve a remission complete.
Specifically, at five years, the overall survival rate was 63% in patients with remission complete, compared to 30% in patients without it. This finding underlines the importance of achieving a remission complete to significantly improve survival rates.
A variety of factors could increase the chances of reaching full maturity. remission
The study also identified several factors that increase the chances of achieving a remission complete pathologic response. These factors include use of the modified FOLFIRINOX neoadjuvant chemotherapy regimen, tumor location in the head of the pancreas, tumors larger than 40 mm at diagnosis, partial or complete radiologic response, and normalization of serum carbohydrate antigen 19-9 after preoperative treatment.
In addition, it was found that the radiotherapy preoperative, and especially the radiotherapy preoperative stereotactic body shaping, were associated with a higher rate of remission complete. However, it is important to note that although the radiotherapy Preoperative stereotactic body shaping was associated with a higher rate of remissionwas also associated with worse overall survival, suggesting that a remission Complete does not always indicate an optimal response to the disease.
Health implications
Despite these promising findings, the study authors caution that a remission A complete pathological evaluation does not necessarily reflect a definitive cure, but it is associated with better overall survival. This nuance is crucial for physicians when considering treatment decisions. The factors identified in this study could help personalize and optimize therapeutic strategies for each patient, increasing the chances of long-term survival.
The study, published online June 18 in the journal JAMA Network Open, highlights the importance of chemoradiotherapy preoperative in the management of pancreatic cancerHowever, several limitations of the study are acknowledged, including the sample size and limited number of events that precluded detailed comparative subanalyses. In addition, no information was collected on patient race or the presence of germline BRCA gene mutations, which could be relevant to the likelihood of obtaining a significant pathological response.
Source consulted here.
